DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

UNH·UnitedHealth Group Incorporated

$.
-. (-.%)
After Hours
High
$433.99
Open
$431.67
Market Cap
389.04B
52W High
$434.30
Low
$423.65
P. Close
$424.58
P/E
32.30
52W Low
$234.60
Fwd P/E
20.24
DailyIQ Est.
$437.58
Technical Score (1D)
82
BUY
News Sentiment
72
BULLISH
UnitedHealth Group surged to a 52‑week high of $434.30 after RBC lifted its price target to $463, citing robust managed‑care trends that bode well for the upcoming Q2 earnings season. The rally is also fueled by growing optimism around AI‑enabled healthcare services, which could lift demand for UnitedHealth’s technology‑driven benefit offerings. RBC’s upgrade underscores the company’s ongoing cost‑control initiatives and a strong earnings trajectory, suggesting that the stock may continue to benefit from a favorable operating environment in the near term. UnitedHealthcare’s launch of a Lifestyle Spending Account offers employers a flexible benefit that may increase member engagement and broaden the company’s employer‑sponsored product suite. The new spending account could also influence utilization patterns and cost structures, potentially affecting the company’s margin profile over the next few weeks. The company’s recent rebound from a sharp decline tied to the tragic death of its former CEO has restored investor confidence, but the volatility that accompanied that episode may still weigh on short‑term sentiment. As the Q2 earnings season approaches, analysts will be closely monitoring revenue growth, margin expansion, and the effectiveness of the new spending account in driving member usage. Traders should also keep an eye on any regulatory developments that could impact benefit design or cost‑control measures, as these could alter the company’s operating dynamics.
Earnings Summary
UnitedHealth Group, a diversified healthcare enterprise, delivers services through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, positioning it as a broad‑spectrum provider in the U.S. and international markets. In the most recent quarter, Q1 2026 revenue rose to $111.7 billion from $113.2 billion in Q4 2025, reflecting a modest decline in top line momentum, while EPS climbed to $7.23 from $2.11 in the prior quarter, indicating a sharp rebound in profitability; the company beat estimates in Q4 2024 and Q1 2026 but missed in Q2 2025 and Q3 2025, showing a mixed beat/miss pattern. Over the past two years, revenue growth has slowed from a high of $113.2 billion in Q3 2025 to $111.7 billion in Q1 2026, yet EPS has swung from $6.81 in Q4 2024 to $7.23 in Q1 2026, underscoring a shift toward margin expansion; the firm has consistently outperformed earnings estimates in most quarters, with the exception of Q1 2025 and Q4 2025. Recent developments include Evercore ISI’s price‑target lift to $480, the first insurer coverage of Guardant Health’s Shield colorectal cancer screening, and a phased reduction of prior‑authorization requirements for rural providers, all of which could support future revenue diversification and margin improvement; the company’s July 16 earnings release will confirm whether the revenue decline and EPS growth align with expectations. Investors should watch for the impact of Shield coverage on utilization, the progress of Optum’s expansion initiatives, and any guidance on cost‑control measures, as these factors will shape the company’s profitability trajectory in the next quarter.

EPS

EstBeatMiss
$1.33$3.02$4.70$6.39$8.07Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.85 - -
Q1'26$6.60$7.23+9.5%
Q4'25$2.12$2.11-0.6%
Q3'25$2.81$2.92+4.0%
Q2'25$4.45$4.08-8.2%
Q1'25$7.29$7.20-1.3%

Revenue

EstBeatMiss
$108.8B$110.5B$112.3B$114.0B$115.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$111.9B - -
Q1'26$109.7B$111.7B+1.9%
Q4'25$115.0B$113.2B-1.5%
Q3'25 - $113.2B -
Q2'25 - $111.6B -
Q1'25 - $109.6B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

UNH Stock Snapshot

UNH is currently trading at $424.50, giving UnitedHealth Group Incorporated a market cap of 389.04B and a P/E ratio of 32.3. Today's range spans $423.65–$433.99, with shares opening at $431.67 and moving down $0.08 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 72/100.

Over the past year UNH has traded between $234.60 and $434.30 - the current price is +80.9% off the 52-week low and -2.3% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $420.46 (range $287.00–$492.00), implying downside of -1.0%.

Algorithmic and quant fund activity in UNH tends to intensify when the technical score crosses the 82/100 threshold - systematic models in large-cap Healthcare names trigger entry signals at these levels, adding momentum to what may have started as fundamental-driven buying. Signal: BUY. Sentiment: bullish (72/100). Price: $424.50 (near 52-week highs). The current P/E ratio stands at 32.3. Annual range: $234.60–$434.30.

The combination of a BUY signal (82/100) and bullish news sentiment (72/100) puts UNH on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 389.04B in Healthcare market cap without immediately moving the stock. At $424.50 (near 52-week highs in the $234.60–$434.30 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.